BACKGROUND: Programmed death-ligand 1 (PD-L1) expression testing is recommended by guidelines for patients with advanced non-small cell lung cancer (NSCLC). The primary objective of the current study was to determine the success rate of PD-L1 testing from cytology cell block samples obtained by bronchoscopic needle aspiration. The secondary objective was the assessment of the difference in specimen adequacy acquired via needles of different gauges. METH-ODS: Patients with NSCLC who underwent bronchoscopic needle aspirations for which PD-L1 testing was requested between November 1, 2016, and February 6, 2017, were included in the current analysis. Patients underwent needle aspiration from intrathoracic adenopathy or a pulmonary lesion. Rapid on-site cytology evaluation was performed in all cases.
INTRODUCTION
According to multiple guidelines, the use of endobronchial ultrasound (EBUS)-guided transbronchial needle aspiration (TBNA) has become the procedure of first choice with which to diagnose and stage locally metastatic lung cancer and is considered the preferred initial diagnostic procedure for the diagnosis of suspected lung cancer. [1] [2] [3] [4] In combination with bronchoscopically obtained cytologic samples, the majority of patients with advanced nonsmall cell lung cancer (NSCLC) are diagnosed by small-volume cytology or biopsy specimens and, in fact, these samples may be the only material available for testing without putting a patient through further invasive sampling. 5 In view of recently approved immune checkpoint inhibitors (eg, nivolumab, atezolizumab, and pembrolizumab), the 2017 National Comprehensive Cancer Network guidelines recommend testing for PD-L1 expression on tumor cells at the time of diagnosis of advanced NSCLC as well as for patients with progression of disease while receiving first-line chemotherapy. In addition, guidelines recommend quantification of PD-L1 expression by immunohistochemical (IHC) membranous staining of tumor cells. Pembrolizumab is approved as first-line therapy with tumor PD-L1 expression of > 50% in patients without epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS1 aberrations, and as second-line therapy for patients experiencing disease progression while receiving platinum-based chemotherapy. Although nivolumab does not require PD-L1 testing for its prescription as second-line chemotherapy, guidelines continue to recommend PD-L1 testing because its expression may provide useful prognostic information with regard to response and survival rate.
1 PD-L1 expression currently is determined by IHC testing and traditionally has required histologic samples. 6, 7 The material obtained on bronchoscopic sampling often is the only specimen available for testing in patients with advanced stage lung cancer. As such, the ability to use cytological specimens reliably for PD-L1 testing, and not require histologic sampling, would be expected to provide an advantage with regard to cost, timeliness, and patient satisfaction.
In the current study, the primary goal was to determine the success rate of PD-L1 testing from cytology cell block samples obtained by bronchoscopic TBNA from either a primary lung nodule/mass or from metastatic mediastinal, hilar, or interlobar lymph nodes in patients with NSCLC. The secondary goal was the assessment of the difference in adequacy for PD-L1 testing of specimens acquired via small-gauge (25-gauge) needles versus larger gauge needles.
MATERIALS AND METHODS

Patient Sample Selection
The current study (IRB17-0392) was approved by the institutional review board of the University of Chicago Medical Center. Between November 1, 2016, and February 6, 2017, a total 22 patients with NSCLC underwent bronchoscopic needle aspirations for which PD-L1 testing was clinically requested.
EBUS-TBNA Procedure for Mediastinal and Hilar Lymph Nodes
As per routine standard of practice, after obtaining informed consent, patients underwent general anesthesia and were intubated by an anesthesiologist. After intubation, an EBUS bronchoscope (Olympus America Inc, Center Valley, Pennsylvania) was guided into the airway under direct vision through the mouth via the endotracheal tube and advanced through the tracheobronchial tree of both lungs.
Complete EBUS exploration of the mediastinal and hilar lymph node stations was performed in a systematic manner. Examination began in N3 lymph nodes and progressed through N2 and N1 lymph nodes sequentially. On examination, if a lymph node >5 mm was identified, EBUS-guided TBNA of the lymph node was performed using dedicated needles. This process continued through the remaining lymph node stations. The choice between the use of a 25-gauge needle (Expect Needle; Boston Scientific, Marlborough, Massachusetts) and a 22-gauge needle (ViziShot Needle, Olympus America Inc) was made at the discretion of the clinician at the time of the procedure.
Bronchoscopic Needle Aspiration Procedure for Endobronchial and Peripheral Lung Nodules
All patients undergoing evaluation of a lung nodule had high-resolution computed tomography scanning performed within 30 days of their procedure. Based on computed tomography review before the procedure, an attempt was made to locate the nodule of interest by direct visualization with a bronchoscope. As per routine standard of practice, after obtaining informed consent, patients underwent general anesthesia and were intubated by an anesthesiologist. After intubation, a bronchoscope (Olympus America Inc, Center Valley) was guided into the airway under direct vision through the mouth via the endotracheal tube and advanced through the tracheobronchial tree of both lungs. If the nodule was visualized, a TBNA needle (Wang Needle; CONMED Corporation, Utica, New York) was advanced through the working channel and, once the needle sheath was visualized in the airway, it was guided by the bronchoscope to the intended biopsy site. The sheath was placed against the airway wall, after which time an assistant advanced the needle and locked it in place. If the needle did not completely penetrate through the wall, the needle was quickly jabbed forward to assist with penetration. Once the target was penetrated with the needle, an assistant applied suction. The bronchoscopist then briskly agitated the needle through the working channel, after which suction was turned off and the needle was withdrawn back into the sheath and was withdrawn through the working channel. The choice of needle gauge was made at the discretion of the clinician at the time of the procedure.
If a nodule of interest was unable to be visualized directly, we then proceeded with electromagnetic navigation bronchoscopy (ENB). An ENB system (superDimension; Medtronic, Minneapolis, Minnesota) was used for all navigation procedures. ENB planning, sensor placement, registration, and navigation were performed in the standard manner according to the manufacturer's directions. Once the target lesion was located with the steerable extended working channel, the extended working channel was locked in place and the locatable guide was removed. Verification of the nodule of interest was made using radial probe ultrasound (Olympus America Inc) under fluoroscopic imaging (Siemens Medical Solutions USA Inc, Malvern, Pennsylvania). If a lesion was confirmed on radial ultrasound, we then proceeded with biopsy using ENBcompatible brushes, cytology needles, and forceps at the discretion of the clinician at the time of the procedure.
Cytology Sample Processing
After aspiration of a sample, the needle was removed from the bronchoscope and the sample was discharged onto a glass slide, first by replacing the needle stylet followed by an injection of air using an empty syringe attached to the stylet hub. The drop of material dispelled on the glass slide then was smeared with a second slide, resulting in 2 smears. One of the smears was prepared for rapid on-site evaluation using Diff-Quik stain (Medion Diagnostics AG, Dudingen, Switzerland). The second slide was sprayed-fixed with alcohol for future Papanicolaou staining. The remaining aspirate material was placed into CytoLyt solution (Hologic Inc, Marlborough, Massachusetts), and subsequently was processed into a cell block.
Rapid On-Site Evaluation
Slides were stained by a cytotechnologist and reviewed by the cytopathologist on site. Slides were considered adequate if evidence of target sampling was present. This included the presence of lymphocytes or anthracosis, granulomas, or tumor. Examples of inadequate samples included the presence of blood or benign bronchial cells only. If malignant cells were present, the tumor then was subtyped if possible based on cytomorphology alone. If the diagnostic subtype was favored to be non-small cell carcinoma, additional material was obtained and placed into CytoLyt solution. CytoLyt solution was subjectively analyzed by visual inspection for adequacy. A transparent solution was considered inadequate and a cloudy solution or a solution with visible material was considered adequate for the formation of a cell block. The final diagnosis was obtained by performing thyroid transcription factor 1 (TTF-1) and P40 staining on cell blocks from TBNA samples.
PD-L1 IHC Evaluation
PD-L1 IHC was performed using the Abcam anti-PD-L1 antibody 28-8 clone (Abcam, Cambridge, Massachusetts). In the study institution, the pathology laboratory uses the 28-8 antibody clone; although the initial studies regarding pembrolizumab and nivolumab used the 22C3 clone, recent publications have suggested good correlations between the 2 IHC stains. 8 After the deparaffinizing and rehydration of cell blocks, antigen retrieval was performed with a dilution of 1:50 on the Ventana XT platform (Roche Diagnostics, Indianapolis, Indiana). Human tonsil and placenta were used as positive controls. A minimum of 100 viable tumor cells were required on the stained slide from the cell block to be tested for PD-L1. PD-L1 expression was evaluated only in tumor cells. PD-L1-positive tumor cells were counted under high magnification in representative fields from the stained cell block slide. The tumor percentage score was calculated as the percentage of at least 100 viable tumor cells that demonstrated complete or partial membranous staining. For intensity, the following accepted scoring system was used: negative, weak, moderate, and strong ( Figure 1 ).
Statistical Analysis
Continuous variables were reported as the mean (6standard deviation) and were compared using the Student t test (GraphPad Software Inc, La Jolla, California). Categoric variables were expressed as a frequency (percentage). Categorical variables were compared using a Fisher exact test Original Article (GraphPad Software Inc). Comparison of 3 unmatched groups with categorical variables was performed using a Fisher exact test with the Freeman-Halton extension (VassarStats; Vassar College, Poughkeepsie, New York). All tests were 2-sided. A P value of < .05 was set as the standard for determining statistical significance.
RESULTS
Patient Characteristics
A total of 22 patients had PD-L1 testing requested on fine-needle cytology samples obtained via bronchoscopy. There were 12 female and 10 male patients, with an average age of 70.8 years (68.3 years). The cancer subtypes of the samples tested were adenocarcinoma in 54.6% of samples, squamous cell in 27.3% of samples, large cell neuroendocrine in 4.5% of samples, and NSCLC not otherwise specified in 13.6% of samples. The reason patients underwent biopsy with PD-L1 testing was for initial diagnosis in 81.8% of cases and progression of disease in 18.2% (Table 1) .
Cytology Sample Characteristics
Of the 22 samples submitted for PD-L1 testing, material was acquired with a 19-gauge needle in 18.2% of samples, a 21-gauge needle in 9.1% of samples, a 22-gauge needle in 45.5% of samples, and a 25-gauge needle in 27.2% of samples.
With regard to location of sampling, 27.3% of samples were collected from station 7, 4.5% were collected from station 4R, 4.5% were collected from station 4L, 4.5% were collected from station 10L, 4.5% were collected from station 11L, 4.5% were collected from station 11Rs, 4.5% were collected from station 12R, and 45.8% were obtained from a lung mass ( Table 2 ). The method of sample acquisition was via EBUS-TBNA in 72.7% of samples, endobronchial cytology needle fine-needle aspiration (FNA) in 18.2% of samples, and bronchoscopic FNA of a peripheral nodule in 9.1% of samples.
PD-L1 Testing Success
A total of 22 bronchoscopically obtained cytology samples were submitted for PD-L1 testing. Of those, 20 (90.9%) underwent successful PD-L1 testing. The 2 unsuccessful PD-L1 test samples were obtained by EBUS, one with a 22-gauge needle and the other with a 25-gauge needle. The 2 unsuccessful tests were because the cell block had <100 cells, and thus the PD-L1 testing, although indicated, was not performed. There was no statistical difference in PD-L1 test success rates noted between sample methods (P 5 .99) or needle sizes (P 5 1.00) ( Table 3) .
PD-L1 Test Results
Of the 20 cytology samples that underwent successful PD-L1 testing, 14 (70%) demonstrated < 1% membranous expression, 4 samples (20%) were found to have 1% to 49% membranous expression, and 2 samples (10%) demonstrated > 50% membranous expression. The 3 patients with testing on cytology samples that were obtained for progression of disease had PD-L1 staining scores of < 1%.
In 2 cases, a patient had both cytologic and histologic material available from the same biopsy location; in both cases, membranous expression scores were congruent. In 1 patient, histologic and cytologic samples were obtained from separate locations (lung mass and a station 7 lymph node, respectively) 37 days apart and before the patient received any therapy; in this case, the PD-L1 membranous expression score was not congruent, with the histology specimen demonstrating 90% expression and the cytology specimen demonstrating 5% expression. 
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DISCUSSION
The results of the current study add to the limited body of evidence regarding the feasibility of PD-L1 testing on cell blocks from bronchoscopically acquired lung cancer specimens. One recent study of 71 lung cancer specimens obtained by various methodologies (16 of which were obtained via an FNA modality) concluded that PD-L1 IHC testing can be performed on these specimens collected by routine diagnostic methods; however, there was no report regarding the testing failure rate for cytology specimens. 9 In the current study, PD-L1 testing had a 91% success rate. We found that there was no difference in test success when using various needle sizes, including smaller needles (eg, 25-gauge needles). This finding is relevant because the majority of patients with lung cancer are diagnosed with needlebased techniques and using a variety of commercially available needles. The current study was limited by its retrospective methodology and a relatively small sample size. In addition, we did not a priori develop a metric for objectively quantifying the number of cells (eg, < 100, 100-1000, 1000-2000, and >2000 cells) as has been used by some investigators. 10 Future prospective studies should apply such metrics to cell blocks, especially because a previous study has suggested that the correlation of PD-L1 expression between EBUS-TBNA and biopsy specimens increases as the number of tumor cells increases. 10 Such a study should report the PD-L1 expression in each category, the correlation between FNA specimens and biopsy specimens, and the impact on treatment decisions and outcomes.
Despite its limitations, we believe the current study provides evidence supporting the ability to successfully perform PD-L1 testing on bronchoscopically acquired cytological samples, which are the most common samples obtained in the initial workup of lung cancer. Due to tumor heterogeneity, concerns have been raised regarding the reliability and concordance of PD-L1 testing on cytology or small biopsy samples compared with excisional biopsies. 11 There are conflicting findings for studies in which small versus excisional histologic samples were compared. One recent study of 160 patients compared PD-L1 expression on matched biopsy and surgical excision specimens. 12 This study found that there was significant discordance (48%) between the 2 sample types. Another recent study compared the concordance of PD-L1 testing between EBUS-TBNA cytology samples and excisional biopsies of the same lymph nodes. 10 In that study, a total of 5 patients were evaluated; Pearson correlation coefficient testing resulted in a correlation coefficient of 0.93, which is consistent with very good concordance. Given the small sample size, larger studies are required for the evaluation of this issue. In addition to heterogeneity within a tumor, differences also may exist with regard to PD-L1 expression between primary tumor and metastatic tissue. In the same study cited above, 16 patients were evaluated for concordance between transbronchial biopsies of the primary lung tumor and EBUS-TBNA samples of metastatic lymph nodes; Pearson correlation coefficient testing resulted in a correlation coefficient of 0.75. 10 Another study comparing PD-L1 expression in primary tumor and metastatic tissue among 161 patients with lung adenocarcinoma found an overall concordance rate of 75%. 13 Overall, these results suggest a moderate-to-strong correlation for PD-L1 expression between primary and metastatic tumor tissue. In the current case series, we encountered one patient who had discordant PD-L1 expression between the primary tumor and metastatic lymph node. Although additional studies are needed to better define this topic, if this relationship holds true, one could argue for the sampling and testing of both metastatic and primary cancer tissue given the benefits of immune checkpoint inhibitors. 14 In the current study, we performed PD-L1 testing using the Abcam anti-PD-L1 antibody 28-8 clone on the Ventana XT platform. Debate exists regarding the interchangeability of different PD-L1 assays and, at the time of publication, each immune checkpoint agent has its own specific accompanying PD-L1 test. One recent study of commercially available PD-L1 IHC assays found high agreement (>90%) between the Ventana SP263, Dako 22C3 (Agilent Technologies, Santa Clara, California), and Dako 28-8 tests. 8 Another recent study found concordance between the Dako 28-8, Dako 22C3, and Leica Bond E1L3N assays (Leica Biosystems Inc, Buffalo Grove, Illinois). 15 That same study found the Ventana SP142 assay to be discordant. As long as PD-L1 membrane expression remains the standard qualifying test for, and prediction of response to, immune checkpoint inhibitors, further studies are required to better define and standardize testing platforms.
The results of the current case series suggest that bronchoscopically obtained cytology samples are feasible for PD-L1 testing in patients with lung cancer. In the current study, there was no difference noted between different gauge needles with regard to adequacy for PD-L1 testing.
